Based on data collected from different sources by our team,
there are indicators that suggest that this company is no longer active. However, this information may not be accurate.
If you believe this information should be updated, please .
For more details, you can read our .
Tisbury Pharmaceuticals is a preclinical-stage pharmaceutical company focused on the discovery, development, and commercialization of treatments for primary open-angle glaucoma. The company's clinical candidate, R-801, accelerates flow through the trabecular meshwork via redox catalysis and K+-ATP channel activation.